Get started
Author

Imen Guizani

Observed names: I Guizani, I. Guizani
Institution: Hôpital La Rabta
ORCID: 0000-0001-9477-8937
Observed ORCID: 0000-0001-9477-8937
OpenAlex ID: A5088676023
SARS-CoV-2 and pathological matrix remodeling mediators
2021 · Imen Guizani, Nesrine Fourti, et al. · Inflammation Research · 33
PDF
Matrix metalloproteinase-3 predicts clinical cardiovascular outcomes in patients with coronary artery disease: a 5 years cohort study
2019 · Imen Guizani, Wiem Zidi, et al. · Molecular Biology Reports · 26
Metabolic Syndrome, Independent Predictor for Coronary Artery Disease
2015 · Wiem Zidi, Monia Allal-Elasmi, et al. · Clinical Laboratory · 20
Inflammations mediators and circulating levels of matrix metalloproteinases: Biomarkers of diabetes in Tunisians metabolic syndrome patients
2016 · Yosra Zayani, Nargess El Golli, et al. · Cytokine · 15
Matrix metalloproteinase 3 and 9 as genetic biomarkers for the occurrence of cardiovascular complications in coronary artery disease: a prospective cohort study
2022 · Imen Guizani, Wiem Zidi, et al. · Molecular Biology Reports · 9
MICA‐129 Met/Val polymorphism could be a genetic biomarker for Familial Breast Cancer in the Tunisian population
2020 · Nesrine Ouni, Arij Ben Chaaben, et al. · International Journal of Immunogenetics · 8
Association of matrix metalloproteinase 3 and endogenous inhibitors with inflammatory markers in mitral valve disease and calcification
2018 · Sonia Aloui, Wiem Zidi, et al. · Molecular Biology Reports · 5
Abnormal Circulating Levels of Metalloproteinase and Their Inhibitor in Hypertensive Patients
2016 · Yosra Zayani, Monia Allal-Elasmi, et al. · Clinical Laboratory · 2
Association of metabolic syndrome with coronary artery disease and major adverse cardiovascular events: A prospective cohort study
2023 · W. Zidi, I. Guizani, et al. · Archives of cardiovascular diseases
Penicillin therapy effect on MMP-2 and TIMP-2 levels in mitral restenosis after percutaneous mitral commissurotomy
2023 · S. Aloui, W. Zidi, et al. · Archives of cardiovascular diseases
Matrix metalloproteinases and inflammatory mediators: Usefulness of these markers in the progression of mitral stenosis
2021 · S. Aloui, I. Guizani, et al. · Archives of Cardiovascular Diseases Supplements
PDF
Influence plasma levels of matrix metalloproteinase among patients obese with or without metabolic syndrome
2021 · W. Zidi, M. Benkhalifa, et al. · Archives of Cardiovascular Diseases Supplements
PDF
Matrix metalloproteainase-3 polymorphism association with hypertrophic cardiomyopathy
2020 · N Fourti, M Benhlima, et al. · European Heart Journal
PDF
Matrix metalloproteinase-3 and Matrix metalloproteinase-9 genetic variation in a cohort of patients with coronary artery disease
2020 · I. Guizani, Wiem Zidi, et al. · Archives of Cardiovascular Diseases Supplements
Tissue inhibitors of matrix metalloproteinase as a prognostic biomarker of hypertrophic cardiomyopathy
2020 · N. Fourti, W. Zidi, et al. · Archives of Cardiovascular Diseases Supplements
Is matrix metalloprotease-8 a novel predictor of coronary artery disease?
2017 · I. Guizani, W. Zidi, et al. · Archives of Cardiovascular Diseases Supplements
PP.42.21
2015 · I. Guizani, M. Elasmi, et al. · Journal of Hypertension
Works count: 17
Citation count: 118
H-index: 6
I10-index: 4
Year
Topic
Type